新灃集團(01223.HK)預計中期淨虧約1.5億至1.75億港元
格隆匯 8 月 24日丨新灃集團(01223.HK)發佈公告,集團預期截至2020年6月30日止六個月期間錄得淨虧損介乎約1.5億港元至1.75億港元,而集團2019年同期錄得淨利潤約4200萬港元。
公告表示,估計期間財務表現變差主要由於按公平價值計量的金融資產的公平價值虧損約為7200萬港元,而2019年同期為公平價值收益約100萬港元;存貨撥備約為1800萬港元,而2019年同期為撥備約200萬港元;投資物業的公平價值減少約為700萬港元,而2019年同期為投資物業的公平價值增加約4600萬港元;及新冠肺炎(COVID-19)爆發導致集團若干數目業務活動中斷,集團的經營營業額已大幅減少所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.